The specter of generic competition has repeatedly loomed around copyright’s iconic drug, Viagra, triggering questions about the future of similar drug holdings. While initial years saw impressive profits, the exclusivity expiration has opened the way for cheaper alternatives, likely lowering profitability and creating a real hazard for stakeholde